Abstract
MicroRNAs (miRNAs) and promoter hypermethylation are vital epigenetic mechanisms for transcriptional inactivation of tumor suppressor. IRX1 is a newly identified tumor suppressor gene and hypermethylation involves the decreased expression in gastric cancer. However, the microRNA regulatory mechanism on IRX1 expression is still unclear. In this study, we report an IRX1-targeting miRNA-544, which directly targets 3'-UTR of IRX1 gene by luciferase reporter assay. miR-544 suppresses the protein expression of IRX1 gene by Western blot and immunocytochemistry. Ectopic expression of miR-544 promotes cell proliferation and cell cycle progression significantly in vitro on gastric cancer cells. The study suggests that miR-544 is an oncogenic microRNA in gastric cancer. Over expression of miR-544 contributes to the inactivation and low-expression of IRX1 in gastric cancer. These findings are helpful for clarifying the molecular mechanisms involved in gastric carcinogenesis and indicate that miR-544 is a key regulator in switching cell cycle on or off. miR-544 may be a potential molecular target in miRNA-based strategy on gastric cancer.
Keywords: Gastric cancer, IRX1, MiR-544, Oncogenic microRNA
Anti-Cancer Agents in Medicinal Chemistry
Title:Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer
Volume: 13 Issue: 2
Author(s): Qiaoming Zhi, Xiaobo Guo, Lei Guo, Rongjuan Zhang, Jinling Jiang, Jun Ji, Jianian Zhang, Jun Zhang, Xuehua Chen, Qu Cai, jianfang Li, Bingya Liu, Zhenggang Zhu and Yingyan Yu
Affiliation:
Keywords: Gastric cancer, IRX1, MiR-544, Oncogenic microRNA
Abstract: MicroRNAs (miRNAs) and promoter hypermethylation are vital epigenetic mechanisms for transcriptional inactivation of tumor suppressor. IRX1 is a newly identified tumor suppressor gene and hypermethylation involves the decreased expression in gastric cancer. However, the microRNA regulatory mechanism on IRX1 expression is still unclear. In this study, we report an IRX1-targeting miRNA-544, which directly targets 3'-UTR of IRX1 gene by luciferase reporter assay. miR-544 suppresses the protein expression of IRX1 gene by Western blot and immunocytochemistry. Ectopic expression of miR-544 promotes cell proliferation and cell cycle progression significantly in vitro on gastric cancer cells. The study suggests that miR-544 is an oncogenic microRNA in gastric cancer. Over expression of miR-544 contributes to the inactivation and low-expression of IRX1 in gastric cancer. These findings are helpful for clarifying the molecular mechanisms involved in gastric carcinogenesis and indicate that miR-544 is a key regulator in switching cell cycle on or off. miR-544 may be a potential molecular target in miRNA-based strategy on gastric cancer.
Export Options
About this article
Cite this article as:
Zhi Qiaoming, Guo Xiaobo, Guo Lei, Zhang Rongjuan, Jiang Jinling, Ji Jun, Zhang Jianian, Zhang Jun, Chen Xuehua, Cai Qu, Li jianfang, Liu Bingya, Zhu Zhenggang and Yu Yingyan, Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1871520611313020013
DOI https://dx.doi.org/10.2174/1871520611313020013 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pancreatic Amylin as a Centrally Acting Satiating Hormone
Current Drug Targets Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes
Current Topics in Medicinal Chemistry Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Anti-Cancer Agents in Medicinal Chemistry COX-2: Friend or Foe?
Current Pharmaceutical Design Metastatic Cancer Stem Cells: New Molecular Targets for Cancer Therapy
Current Pharmaceutical Biotechnology Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets The Use of Cyclodextrins Nanoparticles for Oral Delivery
Current Medicinal Chemistry Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Surgical Treatment of Endometriosis
Current Women`s Health Reviews Uptake and Metabolism of the Short-Chain Fatty Acid Butyrate, a Critical Review of the Literature
Current Drug Metabolism Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Cancer Gene Therapy by Adenovirus-Mediated Gene Transfer
Current Gene Therapy Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design Marine Bromopyrrole Alkaloids: Synthesis and Diverse Medicinal Applications
Current Topics in Medicinal Chemistry Nutraceuticals for Protection and Healing of Gastrointestinal Mucosa
Current Medicinal Chemistry Saccharomyces cerevisiae (Baker’s Yeast) as an Interfering RNA Expression and Delivery System
Current Drug Targets Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry